Oxaliplatin

CHEMBL414804 Phase 4 معتمد Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
397.3 g/mol
LogP
Phase
4

A platinum-based chemotherapy drug binding to DNA to prevent cancer cell replication in colorectal cancer.

الوزن الجزيئي

397,2900 g/mol

TPSA

76,60 Ų

المجالات العلاجية

Pharmacokinetics (PK)

Pharmacodynamics (PD)

SMILES

C1CC[C@H]([C@@H](C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2]

InChI

InChI=1S/C6H12N2.C2H2O4.Pt/c7-5-3-1-2-4-6(5)8;3-1(4)2(5)6;/h5-8H,1-4H2;(H,3,4)(H,5,6);/q-2;;+2/t5-,6-;;/m1../s1

Molecular Formula

C8H14N2O4Pt

HBD / HBA

4 / 6

الروابط القابلة للدوران

0

الذرات الثقيلة

15

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

الأسئلة الشائعة

A platinum-based chemotherapy drug binding to DNA to prevent cancer cell replication in colorectal cancer.

Yes, Oxaliplatin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL414804. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 9887053. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

إخلاء المسؤولية الطبية

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.